Last reviewed · How we verify
Clotinab
At a glance
| Generic name | Clotinab |
|---|---|
| Also known as | Clotinab, Gp IIb/IIIa inhibitor |
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Deferred Stenting in Patients With Anterior Wall STEMI (NA)
- Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients (PHASE2)
- ClearWay Rx Readmission Registry
- Aspirin Resistance and Percutaneous Coronary Intervention (PCI) (PHASE2)
- ReoPro and Retavase to Treat Acute Stroke (PHASE2)
- Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients (PHASE2)
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (PHASE3)
- Stroke Prevention With Abciximab in Carotid Endarterectomy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |